Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae [1]

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 440-441

  Hansen, Glen T ^a   Metzler, Kelli ^a   Drlica, Karl ^c   Blondeau, Joseph M ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL GROWTH; BACTERIUM ISOLATE; BACTERIUM MUTANT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TISSUE LEVEL; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; MUTATION; NAPHTHYRIDINES; STREPTOCOCCUS PNEUMONIAE;

EID: 0037229075     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.440-441.2003     Document Type: Letter

References (16)

1. Blaser, J., B. Stone, M. Groner, and S. Zinner. 1987. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob. Agents Chemother. 31:1054-1060.
2. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
3. Blondeau, J. M., K. Drlica, G. Hansen, and X. Zhao. 2001. The relationship between the mutant prevention concentration (MPC) of fluoroquinolones (FQ) against Streptococcus pneumoniae (SP) and the 24 hour dose response curves, abstr. P71. In Program Abstr. Seventh International Symposium on New Quinolones, Edinburgh, Scotland.
4. Chen, D. K., A. McGeer, J. C. de Azavedo, D. E. Low, et al. 1999. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:233-239.
5. Craig, W. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Drusano, G. L., D. Johnson, M. Rosen, and H. Standiford. 1993. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob. Agents Chemother. 37:483-490.
7. Ho, P., R. Yung, D. Tsang, T. Que, M. Ho, W. Seto, T. Ng, W. Yam, and W. Ng. 2001. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J. Antimicrob. Chemother. 48:659-665.
8. Nagai, K., P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, J. Miciuleviciene, M. Pana, L. Setchanova, M. K. Thege, H. Hupkova, J. Trupl, and P. Urbaskova. 2002. Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 pneumococci from 10 Central and Eastern European countries. Antimicrob. Agents Chemother. 46:371-377.
9. Nagai, K., T. Davies, B. Dewasse, M. Jacobs, and P. Appelbaum. 2001. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin, and moxifloxacin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 48:365-374.
10. Quale, J., D. Landman, J. Ravishankar, C. Flores, and S. Bratu. 2002. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg. Infect. Dis. 8:594-597.
11. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1):S39-S46.
12. Schmitz, F.-J., M. Boos, S. Mayer, D. Hafner, H. Jagusch, J. Verhoef, and A. C. Fluit. 2001. Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:2666-2667.
13. Thomas, J., A. Forrest, S. Bhavnani, J. Hyatt, A. Cheng, C. Ballow, and J. Schentag. 1998. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob. Agents Chemother. 42:521-527.
14. Urban, C., N, Rahman, X. Zhao, N. Mariano, S. Segal-Maurer, K. Drlica, and J. Rahal. 2001. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J. Infect. Dis. 184:794-798.
15. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl. 3):S147-S156.
16. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutants: measurement and potential uses of the mutant selection window. J. Infect. Dis. 185:561-565.